Aims: Many clinical scores for risk stratification in patients with atrial fibrillation have been proposed, and some have been useful in predicting all-cause mortality. We aim to analyse the relationship between clinical risk score and all-cause death occurrence in atrial fibrillation patients. Methods: We performed a systematic search in PubMed and Scopus from inception to 22 July 2017. We considered the following scores: ATRIA-Stroke, ATRIA-Bleeding, CHADS 2 , CHA 2 DS 2 -VASc, HAS-BLED, HATCH and ORBIT. Papers reporting data about scores and all-cause death rates were considered. Results: Fifty studies and 71 scores groups were included in the analysis, with 669,217 patients. Data on ATRIABleeding, CHADS 2 , CHA 2 DS 2 -VASc and HAS-BLED were available. All the scores were significantly associated with an increased risk for all-cause death. All the scores showed modest predictive ability at five years (c-indexes (95% confidence interval) CHADS 2 : 0.64 (0.63-0.65), CHA 2 DS 2 -VASc: 0.62 (0.61-0.64), HAS-BLED: 0.62 (0.58-0.66)). Network meta-regression found no significant differences in predictive ability. CHA 2 DS 2 -VASc score had consistently high negative predictive value (94%) at one, three and five years of follow-up; conversely it showed the highest probability of being the best performing score (63% at one year, 60% at three years, 68% at five years). Conclusion: In atrial fibrillation patients, contemporary clinical risk scores are associated with an increased risk of allcause death. Use of these scores for death prediction in atrial fibrillation patients could be considered as part of holistic clinical assessment. The CHA 2 DS 2 -VASc score had consistently high negative predictive value during follow-up and the highest probability of being the best performing clinical score.
Introduction
Many clinical scores for risk stratification in patients with atrial fibrillation have been proposed, and some have been useful in estimating the baseline risk of major adverse events or to predict disease progression. Indeed, some risk scores, such as the CHADS 2 1 and CHA 2 DS 2 -VASc 2 to estimate the risk thromboembolic events and the HAS-BLED 3 to evaluate baseline bleeding risk, have been recommended in guidelines. 4, 5 Other scores, such as ATRIA 6 or ORBIT, 7 have also been helpful in evaluating bleeding risk. 4, 5 Some clinical scores, especially the CHA 2 DS 2 -VASc score, have been demonstrated to predict adverse outcomes such as mortality, 8 even though they have not been specifically designed to predict the risk of death. The predictive ability of these clinical risk scores for long-term mortality risk in patients with atrial fibrillation has not been systematically reviewed.
Our aim was to perform a systematic review and meta-regression on the available evidence on these clinical factors-based risk scores in predicting mortality amongst atrial fibrillation patients. We considered the following contemporary scores: ATRIAStroke, ATRIA-Bleeding, CHADS 2 , CHA 2 DS 2 -VASc, HAS-BLED, HATCH and ORBIT.
Methods
The present systematic review and meta-analysis was performed according to PRISMA recommendations (http:// www.prisma-statement.org/). We performed a comprehensive literature search using PubMed and Scopus databases from inception up to 22 July 2017. The following scores have been considered: ATRIA-Stroke andBleeding, 6 ,9 CHADS 2 , 1 CHA 2 DS 2 -VASc, 2 HAS-BLED 3 , HATCH 10 and ORBIT. 7 Continuous scores and the standard risk cut-offs were both considered. The full search strategy has been reported in the Supplementary Material online. The electronic search was carried out for peer-reviewed journals and, if applicable, some further additional references were gathered from bibliographies of identified papers and from authors' personal knowledge.
Search results were screened by two co-authors independently (GFR and FP). Disagreements were resolved by collegial discussion with a third co-author (MP). All articles retrieved from the search were evaluated according to titles (mostly excluding non-original data papers, commentaries, viewpoints and all entries that clearly did not qualify for inclusion), abstract and full-text evaluation, sequentially. Studies for which it was possible to clearly ascertain a relevant overlap of cohorts were evaluated according to time of data collection and/or year of publication; accordingly, data collected and/or published more recently were included in the analysis.
Studies selection
To perform our systematic review and meta-analysis, the following selection criteria for studies were considered: (i) only risk scores built with routinely evaluated clinical criteria (i.e. no experimental biomarkers) were considered; (ii) original studies reporting on patients with atrial fibrillation with data available on at least one of the risk scores considered; (iii) a study cohort comprising at least 500 patients; and (iv) available data on mortality events over at least one year of follow-up observation. Exclusion criteria were: i) conference abstracts, letters, comments, case reports and editorials; and ii) studies not published in English.
Data extraction and quality assessment
Data were extracted independently by two of the coauthors (MP and GFR). All data on sample size and scores subgroups, number of events, incidence rates or measures of effect were collected. Data about study characteristics, age and follow-up time were collected. Main outcome considered was occurrence of all-cause death during follow-up observation.
All studies were evaluated independently to assess risk of bias by two co-authors (MP and GFR), according to recommendations of Agency for Healthcare Research and Quality (https://effectivehealthcare.ahrq. gov/topics/cer-methods-guide/overview). Evaluation was performed for selection, performance, attrition, detection and reporting bias categories. Finally, an overall evaluation was performed. All studies have been categorized as low, moderate or high risk of bias.
Data synthesis and analysis
When available, hazard ratios, time-dependent sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were recorded from each study. When not available, hazard ratios and their standard errors were computed according to the methods described by Tierney and colleagues. 11 When not available, time-dependent sensitivities and specificities, PPV and NPV (at the end of follow-up) were computed directly based on the number of patients and events in each score group, and their standard errors estimated via non-parametric bootstrap.
We then performed several separate meta-analyses. After stratifying, where the number of studies to be included was low we decided to use a hierarchical Bayesian meta-regression approach with heterogeneity and informative priors, according to the guidelines previously reported. 12 A linear model was used for describing the pooled effect as a function of moderators (which almost always included follow-up time). When more than one moderator was used, and interactions were desired, we used the method previously described. 13 For sensitivity and specificity at each threshold, and for PPV and NPV at each threshold, a bivariate Bayesian meta-regression model was adopted along similar lines.
A random-effects Bayesian network meta-regression was then performed to compare the area under the curve (AUC) of the scores at each time-horizon by taking into account information arising from direct (multiple scores computed within the same study) and indirect evidence. We selected three time-points to perform the meta-regression analysis (one year, three years, five years). To obtain reliable results and to avoid an over-performance usually related to a low number of groups included, only the scores with at least five available groups were included.
We also computed the surface under the cumulative ranking curves (SUCRAs). Potential publication bias was evaluated through funnel plots and Egger's linear regression test. Inconsistency between direct and indirect sources of evidence was assessed by separating evidence on each comparison into direct and indirect evidence and evaluating their consistency. Sensitivity was evaluated by removing one study at a time and repeating the analysis. A detailed description of the statistical analysis can be found in the Supplementary Material. All analyses were conducted with R version 3.3.3, using the 'GeMTC' and 'adaptMCMC' packages. Several methods were not directly available in any package and appropriate functions to conduct the meta-analyses were written by the authors.
Results
After electronic search a total of 1579 results have been retrieved from PubMed, while 674 results were retrieved from Scopus. Following the selection process (Supplementary Material Figure S1 ), a total of 813 full text papers were assessed for final eligibility. Finally, a total of 50 papers (see the Supplementary Material for references) have been selected for the systematic review and meta-analysis (Table 1) . s4-s54 From the studies selected, we retrieved 71 comparisons of scores groups, as follows: two groups related to ATRIA Bleeding score, no groups for HATCH score, 28 groups for CHADS 2 , 28 groups for CHA 2 DS 2 -VASc, 12 groups for HAS-BLED and one group for the ORBIT Bleeding score.
A large geographical variability was found, with 24 studies coming from Europe, s9,s10,s13,s17-s22,s26,s29,s32,s34, s35,s37,s38,s41,s42,s44,s12,s45,s46,s48,s50 eight from the USA and South America, s6,s16,s23,s24,s28,s30,s40,s52 11 from the Middle East/Asia s7,s8,s54,s14,s15,s25,s27,s31,s33,s47,s51 and seven multinational.
s5,s11,s36,s39,s43,s49,s53 Twenty-three studies were retrospective, s6,s7,s9,s12,s14-s16,s18-s20,s23,s24, s26-s28,s30,s32,s35,s37,s38,s40,s47,s51 while 27 were prospectively evaluated.
s5,s8,s10,s11,s13,s17,s21,s22,s25,s29,s31,s33,s34,s36, s39,s41-s45,s46,s48-s50,s52-s54 According to the type of study, six studies were secondary analyses derived from randomized controlled trials, s5,s23,s36,s39,s43,s53 14 were single centre observational, s9,s10,s15,s18,s21,s22,s25,s30, s31,s34,s41,s45,s46,s52 25 studies were multicentre observational, s6,s8,s11,s13,s14,s16,s17,s19,s20,s24,s26,s27,s29,s32,s33,s35,s37, s38,s42,s44,s48-s51,s54 three studies were derived from population cohort databases s12,s28,s47 and two studies came from insurance databases.
s7,s40 Since only one group with the ORBIT score was included in the systematic review, it was not added to the meta-analysis and network meta-regression. A total of 669,217 patients were included in this systematic review.
Meta-analysis of risk scores
According to the availability of data, each score has been included in the various steps of the meta-analysis. Examining the risk scores as continuous variables, only CHADS 2 , CHA 2 DS 2 -VASc and HAS-BLED have been included (Supplementary Figures S2 to S4 ). After pooling the data together, continuous CHADS 2 score was significantly associated with an increased risk for all-cause death (pooled hazard ratio: 1.13, 95% confidence interval (CI): 1.10-1.16). Similarly, both continuous CHA 2 DS 2 -VASc and HAS-BLED were significantly associated with an increased risk of all-cause death ( Figure 1(a) ). Focusing on the scores' high-risk categories, ATRIA-Bleeding, CHADS 2 , CHA 2 DS 2 -VASc and HAS-BLED scores were included in the analysis (Supplementary Figures S5 to S8 ). For all the scores the high-risk category (ATRIA 4, CHADS 2 2, CHA 2 DS 2 -VASc 2 and HAS-BLED 3) was found associated with an increased risk of all-cause death, with the higher risk ranging from two-fold (CHADS 2 2) to three-fold (CHA 2 DS 2 -VASc 2) (Figure 1(b) ).
Predictivity analysis
In order to evaluate reliability and predictivity of the scores we performed a two-step analysis. All the predictivity analyses have been performed adjusted according to follow-up time and projected to three follow-up time-points (one year, three years, five years).
In the first step we analysed sensitivity, specificity, PPV and NPV for scores' high-risk categories. No data were available for ATRIA score, while only one study s17 reported available data for the HAS-BLED score. Pooled sensitivity and specificity as well as pooled PPV and NPV for CHADS 2 and CHA 2 DS 2 -VASc are reported in Table 2 . The CHADS 2 score reported an overall moderate sensitivity that progressively decreased as the follow-up time increased; meanwhile, specificity progressively increased as the follow-up time got longer, even though modest, ranging up to 56% at five years of follow-up observation. Accordingly, PPV ranged up to 30% at five years, while NPV was steady at around 85% at all timepoints ( Table 2 ). The CHA 2 DS 2 -VASc score showed a consistently high sensitivity (94%) and low specificity (up to 18% at five years). Consequently, CHA 2 DS 2 -VASc had a very low PPV, but the NPV was steadily high at all time-points, ranging from 96% to 94% at one year and five years, respectively). The HAS-BLED score reported both moderate sensitivity (62%) and specificity (71%), with very low PPV (8%) and very high NPV (98%), even though evaluated from data based on just one study. In the second step we determined pooled c-indexes, as reflected by AUCs for each continuous score ( Table 3 ). The ATRIA-Bleeding score reported data only for one year of follow-up. Overall, all the scores reported modest predictive ability consistently at all projected time-points with the CHADS 2 reporting the numerically higher values (AUC: 0.64) ( Table 3) .
For both CHADS 2 and CHA 2 DS 2 -VASc scores, pooled receiving operating characteristic (ROC) curves were built (Supplementary Figure S9) . Both the scores showed similar predictive ability, with the CHADS 2 score being more consistent across the three time-points, while the CHA 2 DS 2 -VASc showed a progressively larger ROC curve (Supplementary Figure S9 , right side).
Network meta-regression and comparison between the scores
According to the methods, to compare scores' performances, we performed a network meta-regression between the scores, projected to the pre-specified follow-up time-points. The network built is shown in Supplementary Figure S10 . Most of the comparisons are between CHADS 2 and CHA 2 DS 2 -VASc scores. Comparison between the AUCs found no significant differences between the scores (Supplementary Figures  S11 to S13) .
The probabilistic analysis, based on rankograms produced by the network meta-regression ( Supplementary  Figures S14 to S16) , produced SUCRAs for each score at each time-point (Figure 2 ). SUCRAs showed that consistently for every time-point the CHA 2 DS 2 -VASc score showed the highest cumulative probability of being the best performing score, particularly at five years of follow-up. Overall, the CHA 2 DS 2 -VASc score showed the highest probability of being the best score, with a 68% cumulative probability (Figure 2 ).
Bias assessment (Supplementary Table S2)
Among the 50 studies included in the systematic review, four studies s15,s18,s44,s48 (8%) were considered at overall medium risk of bias, while only one study s23 (2%) was considered at high risk of bias. Small publication bias was observed for pooled hazard ratio for CHADS 2 Figure S14) and CHA 2 DS 2 -VASc 2 category (Supplementary Figure S15) , as well as pooled specificity for CHA 2 DS 2 -VASc 2 (Supplementary Figure S16) .
category (Supplementary

Sensitivity analysis
In order to establish the reliability of the results presented, a sensitivity analysis was performed for pooled AUCs and SUCRAs. For the pooled AUCs, sensitivity analysis showed for CHADS 2 , CHA 2 DS 2 -VASc and HAS-BLED scores that there were no significant changes when each of the studies included was removed sequentially (Supplementary Tables S3 to S5 ). Only two studies were included for ATRIA pooled AUC, thus no sensitivity analysis was performed. Regarding the SUCRAs, no significant differences were found among direct, indirect and total network evidence (data not shown).
Discussion
In this systematic review and network meta-regression, we showed that all the clinical scores considered (i.e. ATRIA Bleeding, CHADS 2 , CHA 2 DS 2 -VASc and HAS-BLED) were associated with an increased risk of all-cause death, both as continuous and as categorical scores (i.e. high-risk category). Second, the high-risk categories for CHADS 2 and HAS-BLED were characterized by modest to moderate sensitivity and specificity, while the CHA 2 DS 2 -VASc score had high sensitivity and NPV in predicting mortality. Third, all the scores had only modest predictive performance, without any significant difference between each other. Fourth, the CHA 2 DS 2 -VASc score had consistently high negative predictive value during follow-up, and according to SUCRAs, had the highest probability of being the best performing clinical score in predicting all-cause death. Much evidence has been built about the design, the validation and the real-life use of clinical risk scores to predict adverse outcomes, particularly stroke and major bleeding, among atrial fibrillation patients treated or untreated with oral anticoagulant drugs. 14, 15 Furthermore, new scores based on the use of circulating biomarkers have been developed, even though they appear to have only a modest impact on the predictive ability of clinical scores. [16] [17] [18] More recently, other new scores have been proposed to predict net clinical outcomes or occurrence of allcause death. [18] [19] [20] For example, the ABC-Death score was derived from the 'Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation' study, and is based on age, heart failure diagnosis and three different biomarkers: N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac troponin T or troponin I and growth-differentiation factor 15. 18 Overall the ABC-Death score reported good ability in predicting all-cause death, with c-indexes ranging from 0.76 to 0.75 according to troponin T or troponin I use in the derivation cohort, ranging from 0.74 to 0.73 in the validation cohort. 18 Nevertheless, the computation of the score requires the availability of all the biomarkers and would have to be balanced against simplicity and practicality of patient management in everyday clinical practice. Another example, the TIMI-AF score, was derived from the 'Effective Anticoagulation with Factor Xa Next Generation in AF-Thrombolysis in Myocardial Infarction 48' and was based on 16 clinical variables, each given a specific weighting factor in calculating the score. 20 The TIMI-AF score was used to predict a net composite outcome of disabling stroke, life-threatening bleeding or death, but had only a modest predictive ability (c-index: 0.693 in the derivation cohort; c-index: 0.683 in the internal validation cohort). 20 Another score, the 2MACE (metabolic syndrome (doubled), age 75 years (doubled), myocardial infarction or revascularization procedures, congestive heart failure, stroke/transient ischaemic attack/any thromboembolism) score, designed to predict major adverse cardiovascular events (non-fatal or fatal myocardial infarction, coronary revascularization and cardiovascular death), was independently validated in several real-life cohorts, with modest to good predictive performance. 21, 22 Finally, the GARFIELD-AF mortality score was derived from the 'Global Anticoagulant Registry in the FIELD AF' observational registry. 19 The GARFIELD-AF mortality score is based on 18 demographic and clinical characteristics, computed in a complex exponential model, and not feasible for use in routine daily clinical life. There was a c-index of 0.77 for all-cause death in the derivation model and a c-index of 0.74 for three year mortality in the validation cohort. 19 In this study, the CHA 2 DS 2 -VASc score had a modest predictivity for all cause death (c-index: 0.66; 95% CI: 0.64-0.67), lower than the GARFIELD-AF score. 19 Considering our results, obtaining a score with ideal predictive performances is difficult and improved c-indexes usually require an increased number of clinical variables and/or biomarkers, resulting in a progressively more complex model used to derive the c-indexes. Considering that a balance is needed between simplicity and practicality versus predictive value, we should bear in mind that reducing the overall clinical complexity of biological processes, particularly those that can lead to death, could be a challenging process.
Our data clearly demonstrate that the CHA 2 DS 2 -VASc score and, in a more limited extent, HAS-BLED have a very high NPV, and are able to correctly and consistently identify those patients with a very low risk of all-cause death whether over a short, long or very long follow-up timeframe. This evidence stands with the original use of both scores, which were needed to correctly identify those patients not requiring oral anticoagulation, with a 'low risk' CHA 2 DS 2 -VASc score of 0 in males or 1 in females; 2 and for those patients not requiring regular or more frequent follow-up, with the HAS-BLED score. 3 In this light, our results support the use of clinical risk score as a helpful tool in daily clinical practice, assisting physicians in the complex task of predicting patient outcome as well as appropriate decision-making, integrating but not replacing the correct use of clinical assessment.
Patients with atrial fibrillation are clinically complex, often affected by multiple comorbidities 23, 24 and burdened with increased polypharmacy, 25 leading to an increased risk of myocardial infarction, heart failure and death. 26, 27 The use of clinical scores in predicting all-cause death is supported by our data, but they do not supplant clinical practice and are not considered as exhaustive of the complicated clinical and pharmacological interactions of multimorbid atrial fibrillation patients. In a paper investigating the ability of predicting all-cause death in 1051 atrial fibrillation patients, all risk scores presented modest c-indexes ranging from 0.639 for HAS-BLED to 0.706 for CHADS 2 . 28 Our results confirm and extend this evidence, supported by a detailed extensive analysis of available literature.
The preferential use of the CHA 2 DS 2 -VASc score in evaluating the (low) risk of all-cause death in atrial fibrillation patients is supported by the analysis of cumulative probability, indicating that in up to almost 70% of the cases, the CHA 2 DS 2 -VASc score could be the best performing score. These results, paired with the large uptake and ease of calculation, reinforce its use in this specific role. Moreover, our data seem to suggest that the longer the follow-up time, the better the predictive ability of the CHA 2 DS 2 -VASc score. Furthermore, several data also indicate that the CHA 2 DS 2 -VASc score can help in identifying patients more likely to report thromboembolic events and cardiovascular events and death in patients without atrial fibrillation, 8, 29, 30 underlining how its model appears to be effective even beyond the evaluation of thromboembolic risk in atrial fibrillation patients.
Finally, our results need to be interpreted from a clinical point of view. Mortality prediction through clinical risk scores will not enter a specific algorithm for prescribing anticoagulation but may integrate clinical assessment for estimating all-cause death. A pooled analysis derived from Phase 3 trials about non-vitamin K antagonist oral anticoagulants in atrial fibrillation showed that stroke accounted for less than 6% of deaths, 31 hence an estimate of the risk of death may provide useful information beyond antithrombotic prophylaxis (which will be assured in any case). Those patients flagged with a higher risk of death would need to be treated differently, in order to properly account for risk factors and comorbidities. In the last years, accumulating evidence and experts' opinions has focused on underlining the need for atrial fibrillation patients to be treated with more integrated care, which will be able to consider the patient in the entirety of his/her risk burden and manage them with an holistic approach. 32, 33 In order to streamline the integrated care in atrial fibrillation, the ABC pathway has been proposed, 34 based on three main pillars: 'A' -avoid stroke, optimizing anticoagulation management; 'B' -better symptoms management; 'C' -cardiovascular and other comorbidities to be managed and treated appropriately. 34 A recent modelling analysis found that an approach resembling the ABC pathway was associated with a reduced risk of most of the major adverse events, including all-cause death; 35 also, a recent meta-analysis demonstrated that integrated care in atrial fibrillation can reduce both allcause death and cardiovascular death. 36 Use of integrated management would be advisable in those patients identified at high risk of death, using clinical risk scores in the daily clinical practice as manageable and reliable tools integrated with the current appropriate clinical practice.
Limitations
The main limitation of our work is the lack of complete information for all the studies and the score groups, limiting the number of studies included in the comparison analysis. Most of the studies performing direct comparisons are limited to CHADS 2 and CHA 2 DS 2 -VASc, with limited data about the other scores. Notwithstanding these limitations, our paper provides the most extensive analysis on the evidence available about the role of contemporary clinical risk scores in atrial fibrillation patients and the risk of all-cause death.
Conclusions
In atrial fibrillation patients, contemporary clinical risk scores are associated with an increased risk of all-cause death, with no statistically significant differences between the scores. The CHA 2 DS 2 -VASc score had consistently high NPV during follow-up, and the highest probability of being the best performing clinical score. Use of these clinical scores for death prediction in atrial fibrillation patients could be considered as part of their holistic clinical assessment.
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